Thomas F. Deering, Sandeep K. Goyal, Ashish A. Bhimani, Michael Hoosien, Ahmadreza Karimianpour, Kavita P. Krishnasamy, Kent R. Nilsson, Abdullah Omar, Dhanunjaya Lakkireddy, Rakesh Gopinathannair, Aashish Katapadi, Christian Sohns
{"title":"Atrial fibrillation ablation in heart failure patients: Where do we stand in 2023? – State of the art review","authors":"Thomas F. Deering, Sandeep K. Goyal, Ashish A. Bhimani, Michael Hoosien, Ahmadreza Karimianpour, Kavita P. Krishnasamy, Kent R. Nilsson, Abdullah Omar, Dhanunjaya Lakkireddy, Rakesh Gopinathannair, Aashish Katapadi, Christian Sohns","doi":"10.1111/pace.14888","DOIUrl":null,"url":null,"abstract":"Atrial fibrillation (AF) and heart failure are common overlapping cardiovascular disorders. Despite important therapeutic advances over the past several decades, controversy persists about whether a rate control or rhythm control approach constitutes the best option in this population. There is also considerable debate about whether antiarrhythmic drug therapy or ablation is the best approach when rhythm control is pursued. A brief historical examination of the literature addressing this issue will be performed. An analysis of several important clinical outcomes observed in the prospective, randomized studies, which have compared AF ablation to non-ablation treatment options, will be discussed. This review will conclude with recommendations to guide clinicians on the status of AF ablation as a treatment option when considering management options in heart failure patients with atrial fibrillation.","PeriodicalId":19650,"journal":{"name":"Pacing and Clinical Electrophysiology","volume":"13 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pacing and Clinical Electrophysiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/pace.14888","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Atrial fibrillation (AF) and heart failure are common overlapping cardiovascular disorders. Despite important therapeutic advances over the past several decades, controversy persists about whether a rate control or rhythm control approach constitutes the best option in this population. There is also considerable debate about whether antiarrhythmic drug therapy or ablation is the best approach when rhythm control is pursued. A brief historical examination of the literature addressing this issue will be performed. An analysis of several important clinical outcomes observed in the prospective, randomized studies, which have compared AF ablation to non-ablation treatment options, will be discussed. This review will conclude with recommendations to guide clinicians on the status of AF ablation as a treatment option when considering management options in heart failure patients with atrial fibrillation.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
